Reactive Metabolites and Adverse Drug Reactions: Clinical Considerations
- 1 January 2003
- journal article
- review article
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 24 (3) , 229-238
- https://doi.org/10.1385/criai:24:3:229
Abstract
Idiosyncratic reactions can affect many different organ systems, either as -an isolated event (e.g., hepatitis) or as part of a syndrome (e.g., drug hypersensitivity syndrome). Formation of reactive metabolites of drugs in conjunction with a decreased ability for detoxification is believed to be the initiating step in many idiosyncratic reactions. The drug hypersensitivity syndrome, defined by the presence of fever, rash and internal organ involvement, is estimated to occur in approx 1 in 1000 to 1 in 10,000 exposures with drugs such as anticonvulsants sulfonamide antibiotics, allopurinol, and dapsone. Symptoms usually start within 2-8 wk of drug initiation. Serum sicknesslike reaction, most frequently found after 7-14 d of drug exposure, is distinguished by a fever, cutaneous eruption and arthralgias. Medications such as cefaclor, minocycline and bupropion are most frequently implicated in this reaction. In contrast, drug-induced lupus can occur l-2 yr after initiation of medication. Drug-induced lupus is characterized by musculoskeletal complaints and fever and weight loss. Drugs most commonly associated with drug-induced lupus include procainamide, hydralazine, chlorpromazine, isoniazid, and minocycline. Management of patients who develop idiosyncratic reactions includes discontinuation of the implicated drug, initiation of corticosteroids (when appropriate), and symptomatic relief as required. Internal organ involvement, which may initially be asymptomatic, should be monitored. Confirmatory or diagnostic tests are not readily available in most areas, except for research purposes.Keywords
This publication has 54 references indexed in Scilit:
- Metabolic activation in drug allergiesToxicology, 2001
- A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromesClinical Biochemistry, 2000
- Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivityBritish Journal of Pharmacology, 1999
- Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysisThe Lancet, 1998
- Inhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous ImmunoglobulinScience, 1998
- Bioactivation of Phenytoin by Human Cytochrome P450: Characterization of the Mechanism and Targets of Covalent Adduct FormationChemical Research in Toxicology, 1997
- Antinuclear and antinucleolar antibodies in patients with scleroderma- polymyositis overlap syndromeRheumatology, 1996
- Cefaclor serum sickness.1996
- N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes.1995
- Sulfamethoxazole is metabolized to the hydroxylamine in humansClinical Pharmacology & Therapeutics, 1992